Recent Comments

  1. Excellent blog post. I certainly love this
    website. Keep writing!

  2. Congratulations to Jon and Team. Excited to see the results of the next steps in the research on this topic.

  3. Congrats Jon and Team, well done.

  4. I will be there!

  5. We are very sad to say that we don’t have t-shirts this year, due to cost containment. It’s sad!

  6. Do volunteers get a T-shirt? Research Week T-shirts are the best.

  7. We are lucky to have Dr. Brigande and his colleagues here at OHSU doing the very important work that they do! Thank you for highlighting this!

  8. I am glad to see students I have worked with at OHSU going on to great work in other labs.

  9. Sorry, the event organizers didn’t record it.

  10. The federal F&A rate is a completely separate process. We are in the process of negotiating that rate.

  11. Will OHSU be requesting an increase to their federally approved F&A rate for DHHS awards?

  12. Will this be recorded or the minutes/notes available for people that can’t attend this event?

  13. You can just enthusiastically show up at the door.

  14. Do we need to register for this lecture or just arrive enthusiastically at the door on the 24th of October? Really looking forward to this.

  15. Yes! You will be able to find the recording on our archive of Marquam Hill lectures.

  16. In response to inquiries about the new training requirement, please note: Those with NIH funded clinical trials will need to have completed the CITI GCP module by January 1.

  17. Let’s see if this helps. If you are writing a protocol that requires IRB review and you are not having any scientific review of it prior to submitting the protocol, then your protocol will get a scientific review before it goes to the IRB. This could apply to, for example, some kinds of student projects, projects that are funded out of department sources (rather than grant-funded projects), and so on. It wouldn’t apply if your protocols are funded with NIH grants, because your project would be getting a scientific review as part of the grant process. Does that make sense?

  18. There will be flyers eventually! We will make sure you get some.

  19. I don’t quite understand.

    If I’m reading this right, there will be a new scientific review screening of protocols going through the IRB, with hopes of speeding up the process and relieving some of that work from staff only charged with protecting human subjects?

    Also, I don’t understand the second paragraph regarding “…if your protocol was not otherwise externally peer-reviewed…they will be required to undergo internal scientific review by the new committee”.

  20. Will this be recorded at all? I’m interested but cannot get the time off from work unfortunately.

  21. Hi – is there a flyer available for this? I’m afraid we’re rather old school and post paper flyers on a bulletin board in our lab. :-) Thanks!

  22. You mention that metabolic stress may induce the cells to proliferate or change from one cell type to another. Do cells really change or is change manifested in resultant daughter cells? It seems that years ago I heard a speaker insist that cells do not actually change but rather daughter cells resulting from cell division can switch types relative to their parent cell.

  23. Elyse, specifically the rule says that employers could “reduce the amount of pay allocated to base salary (provided that the employee still earns at least the applicable hourly minimum wage) and add pay to account for overtime for hours worked over 40 in the workweek, to hold total weekly pay constant.” The full guidance is here: See Question 9.

  24. You state that “The Department of Labor gives a number of options for compliance besides paying overtime: for example, salaries could be raised to surpass the threshold, comp time could be offered, or base pay could be reduced”. Can you provide references to the idea that pay could be reduced? I have only found the following options to comply with the new rules & regulations: (1) Raise salary and keep the employee exempt from overtime; (2) Pay overtime in addition to the employee’s current salary when necessary; or (3) Evaluate and realign hours and staff workload.


  25. Until a system to keep track of postdoc researchers time is implemented, I don’t see how this will work. Right now leave time for postdocs is tracked 2 ways; 1) honor system, or 2) manually by division admins. I trust OHSU is working on a plan for this section of worker.

  26. As usual, an accurate portrayal of the situation, cleanly written. Thanks Rachel!

  27. Yes! Recordings of past Marquam Hill lectures are available here.

  28. Yikes, sounds terrifying. Are there any way to see these lectures after they’ve occurred or for non-students to see them?

  29. Unfortunately, we are not able to record this seminar.

  30. It looks like a great seminar! Unfortunately I cannot attend. Can you make the recording available perhaps? That would be great, perhaps for several of us.

  31. Will this talk be available online? I’m afraid I will be working during this time period.

  32. We’re not planning to record this, but we can come out to West Campus to do a similar presentation.

  33. Will this be streamed online for those who cannot attend in person? Or a recording posted later for viewing?

  34. Hi Amber – nope! all you need to do is show up.

  35. Will we need to register for this in Compass?

  36. I’d be curious to know what type of fat they were being fed.

  37. Can’t wait to read the results of this trial

  38. This is a fantastic technology for ophthalmologists !
    We use OCT angiography every day, in France.

  39. This is such important research for this patient population, in terms of quality of life. Thanks for this Kerri and also, for all you have done to advance research in this important area.

  40. Tumor monitoring in a drop of blood! Yes, it’s coming. The ability to monitor cancer non-invasively via a finger-prick (not multiple blood tubes) is an unprecedented breakthrough and will be driving the rapid uptake of precision medicine. This technological advancement by CirculoGene Theranostics will further harness tools for cfDNA NGS analysis, profiling circulating genome, and improving test turnaround time, accuracy and treatment outcomes.

  41. Postdocs, thanks so much for everything you do to make OHSU research successful. Your work is critical! We appreciate all that you do.

  42. Thanks for sharing Karen. Good info to have as we share our story with the larger community.

  43. This is good news to have someone capable like Brendan!

  44. Congratulations, Drs. Hong Ma and Shoukhrat Mitalipov! Your paper is indeed a breakthrough.

  45. This is fantastic! Congrats, Dr. Cohen!

  46. My husband is recently mostly retired pathologist who specialized in cervical cancer and I am a mostly retired internal medicine and pap capable Pa
    Georgie scott

  47. Great story, thanks!

  48. I did miss the 3MT event and was crestfallen about that. Thank you for sharing this!

  49. This presentation is intended to provide an overview of this remarkable project, and to inform regarding the disease, heart pumps, and early-stage medical device ventures. It will also include:
    -Dr. Albert Starr; vision and goals
    -Dr. Howard Song & Dr. Jim Mudd; application of mechanical circulatory support in end-stage heart failure, role of artificial heart in therapy
    -Bob Benkowski; medical device development
    -Clyde Taylor; the Company and business issues relevant to commercial device development.

  50. ha ha!

Welcome to the Research News Blog

Welcome to the Research News Blog

OHSU Research News is your portal to information about all things research at Oregon Health & Science University. Visit often for updates on events, discoveries, and important funding information.

Participation Guidelines

Remember: information you share here is public; it isn't medical advice. Need advice or treatment? Contact your healthcare provider directly. Read our Terms of Use and this disclaimer for details.